Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial

Autor: Barco, Stefano, Voci, Davide, Held, Ulrike, Sebastian, Tim, Bingisser, Roland, Colucci, Giuseppe, Duerschmied, Daniel, Frenk, André, Gerber, Bernhard, Götschi, Andrea, Konstantinides, Stavros V., Mach, François, Robert-Ebadi, Helia, Rosemann, Thomas, Simon, Noemi R., Spechbach, Hervé, Spirk, David, Stortecky, Stefan, Vaisnora, Lukas, Righini, Marc, Kucher, Nils, Zetzsche, Stéphanie Roth, Spescha, Rebecca, Leeger, Claudia, Butscheid, Yulia, Probst, Eliane, Micieli, Evy, Forgo, Gabor, Johner, Fabian, Grigorean, Alexandru, Vatsakis, Georgios, Lang, Dagmar Keller, Speck, Silvana Rampini, Hasse, Barbara, Rueegg, Marco, Arnold, Isabelle, Nickel, Christian, Busch, Jeannette, Blondon, Marc, Glauser, Frédéric, Cittone, Micol G., Kessler, Chiara, Gjermeni, Diona, Olivier, Christoph B., Gauchel, Nadine, Biever, Paul, Hobohm, Lukas, Becker, Dorothea, Schindewolf, Marc, Kuenzi, Arnaud, Ulrich, Silvia, Fumagalli, Riccardo M., Bikdeli, Behnood, Gerardi, Teresa, Klok, Frederikus A., Wolf, Simon, Wyss, Dörte
Zdroj: In Research and Practice in Thrombosis and Haemostasis July 2024 8(5)
Databáze: ScienceDirect
Externí odkaz: